About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Poolbeg influenza trial successfully completed

Japanese research offers hope for Fukuyama muscular dystrophy patients

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

Enterome completes patient enrollment for recurrent glioblastoma study

Studying the global spread of antimicrobial resistance

Antibody discovery could lead to new therapies to tackle Strep A

ADVERTISEMENT

Step Pharma announces promising pre-clinical cancer data

New biomaterial can regenerate bones and prevent infections

Vevo Therapeutics launches with $12M to ‘discover better drugs’

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Visiox Pharma announces FDA acceptance of glaucoma new drug application

New targeted drug shows benefit against breast cancer in first phase III trial

ADVERTISEMENT